Sign In
Buy KMDA
$7.14
+0.0400 (+0.563%)
At Close: Jul 31, 2026
Kamada: Earnings Expansion Cycle With Embedded Margin Of Safety
02:28pm, Wednesday, 27'th Aug 2025
KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating levera
3 Reasons Growth Investors Will Love Kamada (KMDA)
01:46pm, Monday, 18'th Aug 2025
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Kamada (KMDA) a New Buy Stock
01:01pm, Thursday, 14'th Aug 2025
Kamada (KMDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KMDA vs. ILMN: Which Stock Is the Better Value Option?
12:40pm, Thursday, 14'th Aug 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for thei
Are Investors Undervaluing Kamada (KMDA) Right Now?
10:41am, Thursday, 14'th Aug 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Kamada Ltd. (KMDA) Q2 2025 Earnings Call Transcript
03:53pm, Wednesday, 13'th Aug 2025
Kamada Ltd. (NASDAQ:KMDA ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call
Kamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to Say
10:31am, Wednesday, 13'th Aug 2025
The headline numbers for Kamada (KMDA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Kamada (KMDA) Q2 Earnings Top Estimates
09:21am, Wednesday, 13'th Aug 2025
Kamada (KMDA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.
Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025
07:00am, Wednesday, 06'th Aug 2025
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd.
KMDA or ACAD: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 04'th Jul 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better
Is Kamada (KMDA) Stock Undervalued Right Now?
10:40am, Friday, 04'th Jul 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
KMDA vs. ACAD: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 18'th Jun 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attract
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
07:00am, Tuesday, 17'th Jun 2025
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for r
Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet
11:01am, Monday, 02'nd Jun 2025
The consensus price target hints at a 106.9% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Are Investors Undervaluing Kamada (KMDA) Right Now?
10:46am, Monday, 02'nd Jun 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
